IP Library › Granted Patent US 12,263,163
Granted Patent B2
US 12,263,163 · App. 18/057,195 · Granted Apr 1, 2025

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor

Inventors: Peter A. Blomgren (Issaquah, WA); Kevin S. Currie (North Bend, WA); Jeffrey E. Kropf (Issaquah, WA); Seung H. Lee (Sammamish, WA); Jennifer R. Lo (Seattle, WA); Scott A. Mitchell (Kenmore, WA); Aaron C. Schmitt (Hamden, CT); Jin-Ming Xiong (Bel Air, MD); Jianjun Xu (Bellevue, WA); Sundaramoorthi Swaminathan (Burlingame, CA); Zhongdong Zhao (Bellevue, WA)
Assignee: Kronos Bio, Inc.
A61K31/4985A61K9/0053A61K31/5377C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,263,163
App. No.
18/057,195
Granted
Apr 1, 2025
Kind
B2
Abstract

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2:

Claims (23)

1. A crystalline form of a succinate salt of Compound 2 :

wherein the crystalline form is succinate Form II; and

wherein crystalline succinate Form II is characterized by an X-ray powder diffractogram comprising characteristic peaks (° 20) at 7.6°±0.2° 20, 7.9°±0.2° 20, 16.3°±0.2° 20, 22.0°±0.2° 20, and 25.0°±0.2 °20.

2. The crystalline form of claim 1 , wherein the crystalline form is further characterized by an X-ray powder diffractogram comprising additional characteristic peaks (° 20) at 11.3°±0.2° 20 and 28.6°±0.2° 20.

3. A pharmaceutical composition comprising the crystalline form of claim 1 and at least one pharmaceutically acceptable vehicle.

4. A method for inhibiting spleen tyrosine kinase activity in a subject, wherein the method comprises administering to the subject in need thereof an effective amount of the crystalline form of claim 1 .

5. The method of claim 4 , wherein the subject suffers from a disorder or disease selected from the group consisting of acute disseminated encephalomyelitis, acute hypersensitivity, acute respiratory distress syndrome, Addison's disease, allergic conjunctivitis, allergic rhinitis, allograft rejection, alveolitis, Alzheimer's disease, appendicitis, asthma, atherosclerosis, atopic dermatitis, autoimmune hemolytic anemia, autoimmune thyroiditis, Behcet's disease, brain injury due to minor trauma, bronchiectasis, cholocystitis, chronic bronchitis, chronic idiopathic thrombocytopenic purpura, chronic inflammatory bowel disease, contact dermatitis, coryza, Crohn's disease, cystic fibrosis, cytokine-induced toxicity, delayed hypersensitivity, dermatomyositis, diabetes, a disease involving leukocyte diapedesis, a disease state due to leukocyte dyscrasia, a disease state due to leukocyte metastasis, eczema, emphysema, encephalitis, endotoxic shock, enteritis, eosinophilic granuloma, essential thrombocythemia, fever due to infection, a food allergy, gastritis, gingivitis, glomerulonephritis, Goodpasture's syndrome, gouty arthritis, graft-versus-host disease, a granulocyte transfusion-associated syndrome, hay fever, a hemorrhage, hepatitis, hyperacute rejection of transplanted organs, hypovolemic shock, inflammatory pelvic disease, irritable bowel syndrome, keloid formation, meningitis, monoarticular arthritis, multiple organ injury syndrome secondary to septicemia, multiple sclerosis, myalgia due to infection, myasthenia gravis, myocarditis, myositis, necrotizing enterocolitis, nephritis, osteoarthritis, osteomyelitis, pancreatitis, Parkinson's disease, pleurisy, pneumonia, pneumonitis, polycystic kidney disease, polycythemia vera, psoriasis, psoriatic arthritis, pulmonary oxygen toxicity, pulmonary sarcoidosis, reperfusion injury of the brain, reperfusion injury of the extremities, reperfusion injury of the myocardium, Reynaud's syndrome, rheumatoid arthritis, scar tissue formation, scleroderma, sepsis, septic shock, silicosis, sinusitis, Sjögren's syndrome, skin sunburn, spinal cord injury due to minor trauma, spondylitis, systemic lupus erythematosus, thermal injury, thyroid-associated ophthalmopathy, tissue graft rejection, toxic shock syndrome, trauma, ulcerative colitis, urethritis, urticaria, uveitis, vasculitis, and vernal conjunctivitis.

6. The method of claim 5 , wherein the asthma, diabetes, hemorrhage, hepatitis, pneumonia, or sepsis is selected from the group consisting of bronchial asthma, type I diabetes mellitus, pulmonary hemorrhage, alcoholic hepatitis, bacterial pneumonia, gram negative sepsis, and gram positive sepsis.

7. The method of claim 4 , wherein:

(a) the subject suffers from a solid tumor; and

(b) the solid tumor is due to a cancer selected from the group consisting of an adrenocorticotropic hormone (ACTH)-producing tumor, bladder cancer, bone cancer, a brain tumor, breast cancer, a cancer of the adrenal cortex, central nervous system cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, gall bladder cancer, gastric cancer, head and neck cancer, hemangiopericytoma, hepatocellular cancer, Kaposi's sarcoma, lung cancer, malignant pleural effusion, melanoma, mesothelioma, myxoid carcinoma, neuroblastoma, neuroendocrine cancer, oral carcinoma, ovarian cancer, pancreatic cancer, peritoneal effusion, prostate cancer, renal cancer, retinoblastoma, round cell carcinoma, soft tissue sarcoma, squamous cell carcinoma, thyroid cancer, a trophoblastic neoplasm, urological cancer, and Wilms tumor.

8. The method of claim 7 , wherein the brain tumor is selected from the group consisting of adult anaplastic astrocytoma, adult glioblastoma multiforme, anaplastic oligodendroglioma, and a glioma.

9. The method of claim 7 , wherein the lung cancer is selected from the group consisting of non-small cell lung cancer and small cell lung cancer.

10. The method of claim 7 , wherein the squamous cell carcinoma is esophageal squamous cell carcinoma.

11. The method of claim 4 , wherein the subject suffers from a disorder or disease selected from the group consisting of acute lymphocytic leukemia, acute myeloid leukemia, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, B-cell acute lymphoblastic leukemia, B-cell lymphoma, B-cell prolymphocytic leukemia, Burkitt's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, cutaneous T-cell lymphoma, extranodal T-cell lymphoma, follicular lymphoma, hairy cell leukemia, immunoblastic large cell lymphoma, juvenile myelomonocytic leukemia, lymphoblastic lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, minimal residual disease, multiple myeloma, myelodysplastic syndrome, a myeloproliferative disease, nodal marginal zone lymphoma (+/−monocytoid B-cells), non-Hodgkin's lymphoma, plasmacytoma, primary effusion lymphoma, primary myelofibrosis, secondary myelofibrosis, small lymphocytic lymphoma, small non-cleaved cell lymphoma, T-cell acute lymphoblastic leukemia, and Waldestrom's macroglobulinemia.

12. The method of claim 11 , wherein the B-cell lymphoma, cutaneous T-cell lymphoma, or non-Hodgkin's lymphoma is selected from the group consisting of diffuse large B-cell lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type, intravascular large B-cell lymphoma, mediastinal large B-cell lymphoma, splenic marginal zone B-cell lymphoma (+/−villous lymphocytes), mycosis fungoides, and indolent non-Hodgkin's lymphoma.

13. The method of claim 12 , wherein the indolent non-Hodgkin's lymphoma is refractory indolent non-Hodgkin's lymphoma.

14. The method of claim 4 , wherein the subject suffers from a disorder or disease selected from the group consisting of acute disseminated encephalomyelitis, asthma, autoimmune hemolytic anemia, chronic obstructive pulmonary disease, Crohn's disease, idiopathic thrombocytopenic purpura, irritable bowel disease, multiple sclerosis, myasthenia gravis, psoriasis, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, and ulcerative colitis.

15. The method of claim 4 , wherein the subject suffers from a disorder or disease selected from the group consisting of asthma, chronic obstructive pulmonary disease, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.

16. The method of claim 4 , wherein the subject suffers from a disorder or disease selected from the group consisting of an allergic disorder, an autoimmune disease, a cancer, and an inflammatory disorder.

17. The method of claim 4 , wherein the subject suffers from a cancer selected from the group consisting of a hematologic malignancy and a solid tumor.

18. The method of claim 4 , wherein the subject suffers from a hematologic malignancy selected from the group consisting of leukemia, lymphoma, and multiple myeloma.

19. The method of claim 4 , wherein the subject suffers from an inflammatory disorder.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2026
From: KRONOS BIO, INC.
To: IGNOTA LABS LIMITED
Reel/Frame 075588/0486 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2026
From: GILEAD SCIENCES, INC.
To: KRONOS BIO, INC.
Reel/Frame 075588/0529 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2026
From: BLOMGREN, PETER A.; CURRIE, KEVIN S.; KROPF, JEFFREY E.; LEE, SEUNG H.; LO, JENNIFER R.; MITCHELL, SCOTT A.; SCHMITT, AARON C.; XIONG, JIN-MING; XU, JIANJUN; ZHAO, ZHONGDONG; SWAMINATHAN, SUNDARAMOORTHI
To: GILEAD SCIENCES, INC.
Reel/Frame 074637/0319 →
Continuity (6)
Continuation 17082595 · Oct 28, 2020
Division 16413458 · May 15, 2019
Continuation 15945685 · Apr 4, 2018
Continuation 14578973 · Dec 22, 2014
Provisional Application 61920407 · Dec 23, 2013
Related Publication 20230158023A1 · May 25, 2023
References Cited (327)
US 5593997A · Dow et al. · 1997 [cited by applicant]
US 5658857A · Andree et al. · 1997 [cited by applicant]
US 5783576A · Roos et al. · 1998 [cited by applicant]
US 5846514A · Foster et al. · 1998 [cited by applicant]
US 6334997B1 · Foster et al. · 2002 [cited by applicant]
US 6911443B2 · Yura et al. · 2005 [cited by applicant]
US 6919340B2 · Currie et al. · 2005 [cited by applicant]
US 6919341B2 · Paruch et al. · 2005 [cited by applicant]
US 7160885B2 · Currie et al. · 2007 [cited by applicant]
US 7189723B2 · Mitchell et al. · 2007 [cited by applicant]
US 7259164B2 · Mitchell et al. · 2007 [cited by applicant]
US 7312341B2 · Desimone et al. · 2007 [cited by applicant]
US 7405295B2 · Currie et al. · 2008 [cited by applicant]
US 8354526B2 · Ding et al. · 2013 [cited by applicant]
US 8440667B2 · Mitchell et al. · 2013 [cited by applicant]
US 8450321B2 · Mitchell et al. · 2013 [cited by applicant]
US 8455493B2 · Mitchell et al. · 2013 [cited by applicant]
US 8546370B2 · Okram et al. · 2013 [cited by applicant]
US 8697699B2 · Mitchell et al. · 2014 [cited by applicant]
US 8748607B2 · Mitchell et al. · 2014 [cited by applicant]
US 8765761B2 · Mitchell et al. · 2014 [cited by applicant]
US 8796270B2 · Mitchell · 2014 [cited by applicant]
US 8962835B2 · Mitchell et al. · 2015 [cited by applicant]
US 9120811B2 · Mitchell et al. · 2015 [cited by applicant]
US 9212191B2 · Mitchell et al. · 2015 [cited by applicant]
US 9290505B2 · Blomgren et al. · 2016 [cited by applicant]
US 9376441B2 · Currie et al. · 2016 [cited by applicant]
US 9382256B2 · Casteel et al. · 2016 [cited by applicant]
US 9504684B2 · Blomqren et al. · 2016 [cited by applicant]
US 9562056B2 · Blomgren et al. · 2017 [cited by applicant]
US 9567348B2 · Mitchell et al. · 2017 [cited by applicant]
US 9657023B2 · Elford et al. · 2017 [cited by applicant]
US 9687492B2 · Di Paolo et al. · 2017 [cited by applicant]
US 9707236B2 · Di Paolo et al. · 2017 [cited by applicant]
US 9796718B2 · Mitchell et al. · 2017 [cited by applicant]
US 9918939B2 · Casteel · 2018 [cited by applicant]
US 9949932B2 · Casteel et al. · 2018 [cited by applicant]
US 9968601B2 · Blomgren et al. · 2018 [cited by applicant]
US 9974792B2 · Di Paolo · 2018 [cited by applicant]
US 10005774B2 · Blomgren et al. · 2018 [cited by applicant]
US 10080756B2 · Di Paolo et al. · 2018 [cited by applicant]
US 10092583B2 · Blomqren et al. · 2018 [cited by applicant]
US 10093684B2 · Blomgren et al. · 2018 [cited by applicant]
US 10111882B2 · Abella et al. · 2018 [cited by applicant]
US 10266539B2 · Elford et al. · 2019 [cited by applicant]
US 10342794B2 · Blomgren et al. · 2019 [cited by applicant]
US 10828299B2 · Blomgren et al. · 2020 [cited by applicant]
US 10842803B2 · Blomgren et al. · 2020 [cited by applicant]
US 11339168B2 · Andres et al. · 2022 [cited by applicant]
US 11517570B2 · Blomgren et al. · 2022 [cited by applicant]
US 12152037B2 · Andres · 2024 [cited by applicant]
US 20020037852A1 · Browning et al. · 2002 [cited by applicant]
US 20030212073A1 · Currie et al. · 2003 [cited by applicant]
US 20040063715A1 · Paruch et al. · 2004 [cited by applicant]
US 20040067951A1 · Desimone et al. · 2004 [cited by applicant]
US 20040072081A1 · Coleman et al. · 2004 [cited by applicant]
US 20040072835A1 · Paruch et al. · 2004 [cited by applicant]
US 20040102455A1 · Burns et al. · 2004 [cited by applicant]
US 20040220189A1 · Sun et al. · 2004 [cited by applicant]
US 20050009832A1 · Sun et al. · 2005 [cited by applicant]
US 20050054648A1 · Mitchell et al. · 2005 [cited by applicant]
US 20050054649A1 · Currie et al. · 2005 [cited by applicant]
US 20050085484A1 · Mitchell et al. · 2005 [cited by applicant]
US 20050090499A1 · Currie et al. · 2005 [cited by applicant]
US 20050101604A1 · Currie et al. · 2005 [cited by applicant]
US 20050222199A1 · Hayman et al. · 2005 [cited by applicant]
US 20050288295A1 · Currie et al. · 2005 [cited by applicant]
US 20060069084A1 · Burns et al. · 2006 [cited by applicant]
US 20060084650A1 · Dong et al. · 2006 [cited by applicant]
US 20060183746A1 · Currie et al. · 2006 [cited by applicant]
US 20070027135A1 · Bruncko et al. · 2007 [cited by applicant]
US 20070072860A1 · Bruncko et al. · 2007 [cited by applicant]
US 20070117804A1 · Zhao et al. · 2007 [cited by applicant]
US 20090197809A1 · Anderson et al. · 2009 [cited by applicant]
US 20100305122A1 · Bruncko et al. · 2010 [cited by applicant]
US 20100305125A1 · Borchardt et al. · 2010 [cited by applicant]
US 20110002989A1 · Curatolo et al. · 2011 [cited by applicant]
US 20110152273A1 · Arikawa et al. · 2011 [cited by applicant]
US 20120157470A1 · Catron et al. · 2012 [cited by applicant]
US 20130267496A1 · Mitchell et al. · 2013 [cited by applicant]
US 20130338142A1 · Blomgren et al. · 2013 [cited by applicant]
US 20140051696A1 · Lannutti et al. · 2014 [cited by applicant]
US 20140148430A1 · Blomgren et al. · 2014 [cited by applicant]
US 20150175626A1 · Cagulada et al. · 2015 [cited by applicant]
US 20150237860A1 · Anderson et al. · 2015 [cited by applicant]
US 20160168155A1 · Fung et al. · 2016 [cited by applicant]
US 20160220573A1 · Di Paolo et al. · 2016 [cited by applicant]
US 20160368918A1 · Blomgren et al. · 2016 [cited by applicant]
US 20160375019A1 · Di Paolo et al. · 2016 [cited by applicant]
US 20170035755A1 · Blomgren et al. · 2017 [cited by applicant]
US 20170217967A1 · Elford et al. · 2017 [cited by applicant]
US 20180071302A1 · Abella et al. · 2018 [cited by applicant]
US 20180071303A1 · Abella et al. · 2018 [cited by applicant]
US 20180086769A1 · Armistead et al. · 2018 [cited by applicant]
US 20180117052A1 · Di Paolo et al. · 2018 [cited by applicant]
US 20180280387A1 · Blomgren et al. · 2018 [cited by applicant]
CA 2175837 · 1995 [cited by applicant]
CN 101124227 · 2008 [cited by applicant]
DE 4337609 · 1995 [cited by applicant]
EP 0480713 · 1992 [cited by applicant]
JP 2001302667 · 2001 [cited by applicant]
JP 2004528295 · 2004 [cited by applicant]
JP 2005530739 · 2005 [cited by applicant]
JP 2008519843 · 2008 [cited by applicant]
NZ 593460 · 2013 [cited by applicant]
WO WO8804298 · 1988 [cited by applicant]
WO WO9512594 · 1995 [cited by applicant]
WO WO9604298 · 1996 [cited by applicant]
WO WO96004298 · 1996 [cited by applicant]
WO WO96034866 · 1996 [cited by applicant]
WO WO9634866 · 1996 [cited by applicant]
WO WO9928322 · 1999 [cited by applicant]
WO WO0127119 · 2001 [cited by applicant]
WO WO01027119 · 2001 [cited by applicant]
WO WO0134119 · 2001 [cited by applicant]
WO WO0147495 · 2001 [cited by applicant]
WO WO01083485 · 2001 [cited by applicant]
WO WO0183485 · 2001 [cited by applicant]
WO WO02010170 · 2002 [cited by applicant]
WO WO0210170 · 2002 [cited by applicant]
WO WO02030428 · 2002 [cited by applicant]
WO WO0230428 · 2002 [cited by applicant]
WO WO02060492 · 2002 [cited by applicant]
WO WO02066481 · 2002 [cited by applicant]
WO WO02076985 · 2002 [cited by applicant]
WO WO03070732 · 2003 [cited by applicant]
WO WO03089434 · 2003 [cited by applicant]
WO WO04022562 · 2004 [cited by applicant]
WO WO04026310 · 2004 [cited by applicant]
WO WO04026867 · 2004 [cited by applicant]
WO WO04072080 · 2004 [cited by applicant]
WO WO04072081 · 2004 [cited by applicant]
WO WO05005429 · 2005 [cited by applicant]
WO WO05014599 · 2005 [cited by applicant]
WO WO05019220 · 2005 [cited by applicant]
WO WO05047290 · 2005 [cited by applicant]
WO WO05085252 · 2005 [cited by applicant]
WO WO06009769 · 2006 [cited by applicant]
WO WO06044687 · 2006 [cited by applicant]
WO WO06053121 · 2006 [cited by applicant]
WO WO08025821 · 2008 [cited by applicant]
WO WO08033854 · 2008 [cited by applicant]
WO WO09039397 · 2009 [cited by applicant]
WO WO09070639 · 2009 [cited by applicant]
WO WO09077334 · 2009 [cited by applicant]
WO WO09102252 · 2009 [cited by applicant]
WO WO09137596 · 2009 [cited by applicant]
WO WO09156284 · 2009 [cited by applicant]
WO WO10000633 · 2010 [cited by applicant]
WO WO10006947 · 2010 [cited by applicant]
WO WO10027500 · 2010 [cited by applicant]
WO WO11074961 · 2011 [cited by applicant]
WO WO11112995 · 2011 [cited by applicant]
WO WO12147832 · 2012 [cited by applicant]
WO WO13188856 · 2013 [cited by applicant]
WO WO14028665 · 2014 [cited by applicant]
Abrisqueta et al., Personalizing treatment for chronic lymphocytic leukemia, Expert Review of Hematology, 2011, 4(1):27-35. [cited by applicant]
Ackler et al., 2012, Navitoclax (ABT-263) and bendamustine rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo, British Journal of Pharmacology, 167:881-891. [cited by applicant]
Al-Dabbagh et al., 1984, Species Differences in Oxidative Drug Metabolism: Some Basic Considerations, Archives of Toxicology, Suppl. 7:219-231. [cited by applicant]
Ashizawa, 2002, en/kesshokei no saitekika to kesshokagijutsu (optimization of salt/crystal form and crystallization technique), Pharm Tech Japan, 18(10):81-96. [cited by applicant]
Bastin et al., 2000, Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities, Organic Process Research and Development, American Chemical Society, 4(5):427-435. [cited by applicant]
Berge et al., Jan. 1977, Pharmaceutical Salts, Journal of Pharmaceutical Sciences, 66(1):1-19. [cited by applicant]
Blazar et al., 2013, Advances in graft-versus host disease biology and therapy, Nat Rev Immunol., 12(6):443-458. [cited by applicant]
Bouloc et al., 2010, Structure-based design of imidazo[1,2-α]pyrazine derivatives as selective inhibitors of Aurora kinase in cells. Bioorganic & Medicinal Chemistry Letters, 20:5988-5993. [cited by applicant]
Brittain, 2009, Theory and principles of polymorphic systems, in Polymorphism in Pharmaceutical Solids, Informa Healthcare, New York, pp. 1-23. [cited by applicant]
Buchner et al., Jun. 2010, Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia, Blood, 115(22):4497-4506. [cited by applicant]
Bundgaard, H., (1985). Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities, Elsevier Science Publishers, B.V., The Netherlands, p. 1. [cited by applicant]
Burke et al., 2014, A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor, Oncotarget, 5(4):908-915. [cited by applicant]
Burrell et al., 2013, The causes and consequences of genetic heterogeneity in cancer evolution, Nature, 501:338-345. [cited by applicant]
CancerConnect.com, Aug. 17, 2013, Ibrutinib Highly Active in Patients with Chronic Lymphocytic Leukemia with 17p Deletion, 2 pp. [cited by applicant]
ClinicalTrials.gov, Jun. 2013, A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies, NCT01799889, 5 pp. [cited by applicant]
Currie et al., 2014, Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase, J. Med. Chem., 57:3856-3873. [cited by applicant]
Dean, 2000, Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development, Curr. Pharm Des. 6(10):Preface, 1 p. [cited by applicant]
Dean, D.C. (2000). “Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for drug Discovery and Development,” Curr. Pharm Des. 6(10): Preface, 1 page. [cited by applicant]
Ding et al., 2002, A Combinatorial Scaffold Approach Toward Kinase-Directed Heterocycle Libraries, J. Am Chem Soc., 124(8):1594-1596. [cited by applicant]
Ding, S. et al. (2002) “A Combinatorial Scaffold Approach Toward Kinase-Directed Heterocycle Libraries,” J. Am Chem Soc., 124(8):1594-1596. [cited by applicant]
Elder et al., 2010, The Utility of Sulfonate Salts in Drug Development, J Pharm Sci, 99(7)2948-2961. [cited by applicant]
Evans, 1981, Synthesis of Radiolabeled Compounds, J. Radioanal. Chem. 64(1-2):9-32. [cited by applicant]
Flynn, Aug. 2014, B cells, T follicular helpers, and germinal centers as facilitators of chronic Graft-versus-Host disease. Doctoral Dissertation, University of Minnesota, 182 pp. [cited by applicant]
Gavezzotti, 1994, Are Crystal Structures Predictable? Acc. Chem. Res. 27(10):309-314. [cited by applicant]
GenBank Accession No. AY050647.1, created on Oct. 7, 2001, located at<http://www.ncbi.nlm.nih.gov/nuccore/AY050647.1>, last visited on Dec. 28, 2011, 1 page. [cited by applicant]
Golub et al., Oct. 15, 1999, Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science, 286″531-537. [cited by applicant]
Hackam et al., 2006, Translation of Research Evidence From Animals to Humans, JAMA, 296(14):1731-1732. [cited by applicant]
Hill et al., 2013, B-Cell Antigen Receptor Signaling in Chronic Lymphocytic Leukemia: Therapeutic Targets and Translational Opportunities, International Reviews of Immunology, 32:377-396. [cited by applicant]
Hirayama, Jul. 25, 2008, Handbook for creating organic compound crystals—principle and technical know-how, Maruzen KK, pp. 17-23, 37-40, 45-51 and 57-65. [cited by applicant]
Jeffrey et al., 1998, Phosphodiesterase III and V Inhibitors on Pulmonary Artery from Pulmonary Hypertensive Rats: Differences Between Early and established Pulmonary Hypertension, J. Cardiovascular Pharmacology, 32(2):… [cited by applicant]
Jordan Mar. 2003, Tamoxifen: A Most Unlikely Pioneering Medicine, Nature Reviews: Drug Discovery 2:205-213. [cited by applicant]
Kabalka et al., 1989, The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron 45(21):6601-6621. [cited by applicant]
Kojima, Sep. 2008, Iyakuhin Kaihatsu ni okeru kettushousei sentaku no kouritsuka womezashite (Aiming at efficient crystallinity selection in medicine development), Journal of Pharmaceutical Science and Technology, Japan… [cited by applicant]
Krisenko et al., Jan. 2015, Calling in SYK: SYK's Dual Role as a Tumor Promoter and Tumor Suppressor in Cancer, Biochim Biophys Acta., 1853(1):254-263. [cited by applicant]
Kuhnz et al., Jun. 11, 1998, Predicting the Oral Bioavailab ty of 19-Nortestosterone Progestins In Vivo From Their Metabolic Stab ty in Human Liver Microsomal Preparation In Vitro, The American Society for Pharmacology … [cited by applicant]
Le Huu et al., 2014, Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-vershost disease, Journal of Dermatological Science, 74:214-221. [cited by applicant]
Lumma et al., 1983, Piperazinylimidazo [1,2-α]pyrazines with Selective affinity for in Vitro adrenergic Receptor Subtypes, J. Med. Chem. 26(3):357-363. [cited by applicant]
Ma et al., 2011, Signal transduction inhibitors in chronic lymphocytic leukemia, Current Opinion in Oncology, 23:601-608. [cited by applicant]
Merino et al., 2012, Bcl-2, Bcl-xl, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells, Blood. 119(24):5807-5816. [cited by applicant]
National Cancer Institute, 2017, Cancer Types, A to Z List of Cancer Types, 8 pp. [cited by applicant]
Oracova et al., 1996, Drug-Protein Binding Studies New Trends in Analytical and Experimental Methodology, J Chromatography B, 677:1-28. [cited by applicant]
Owen et al., 2012, Obinutuzumab for the treatment of lymphoproliferative disorders, Expert Opinion Biol. Ther. 12(3):343-351. [cited by applicant]
Paulekuhn et al., 2007, Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database, J. Med. Chem., 50:6665-6672. [cited by applicant]
Roberts et al., 2012, Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease, J Clin Oncol, 30:488-496. [cited by applicant]
Serajuddin, 2007, Salt formation to improve drug solubility, Advanced Drug Delivery Reviews, 59:603-616. [cited by applicant]
Silverman, 1992, Prodrugs and drug delivery systems, in The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, CA, pp. 352-400. [cited by applicant]
Stenberg et al., 2000, KinMutBase, a Database of Human Disease-Causing Protein Kinase Mutations, Nucleic Acids Research 28(1):369-371. [cited by applicant]
Takata, 2007, API form screening and selection in drug discovery stage, Pharmstage, 6(10):20-25. [cited by applicant]
Taylor et al., 1984, Hydrogen-Bond Geometry in Organic Crystals, Acc. Chem Res. 17:320-326. [cited by applicant]
Vassilev et al., 2004, Therapeutic Potential of Inhibiting Bruton's Tyrosine Kinase, (BTK), Current Pharmaceutical Design, 10:1757-1766. [cited by applicant]
Vippagunta et al., 2011, Crystalline solids, Advanced Drug Delivery Reviews 48:3-26. [cited by applicant]
Vitze et al., 1999, New Imidazo [1,2-a]pyrazine Derivatives with Bronchodilatory and Cyclic Nucleotide Phosphodiesterase Inh tory Activities, Bioorganic and Medicinal Chemistry 7:1059-1065. [cited by applicant]
Willander et al, 2013, NOTCH1 Mutations Influence Survival in Chronic Lymphocytic Leukemia Patients, BMC Cancer , 13:274, 6 pp. [cited by applicant]
Zaragoza Dorwald, 2005, Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim; WILEY-VCH Verlag Gmbh & Co., Preface, 2 p. [cited by applicant]
European Communication mailed on Jun. 18, 2013, for EP Patent Application No. 11 709 600.8 filed on Mar. 11, 2011, 6 pages. (39.45). [cited by applicant]
European Communication mailed on Jun. 6, 2013, for EP Patent Application No. 09 832 228.2 filed on Jun. 21, 2011, 5 pages. (27.49). [cited by applicant]
European Communication mailed on Oct. 24, 2012, for European Patent Application No. 09710901.1, filed on Feb. 12, 2009, five pages. (38.43). [cited by applicant]
Examination Report for AU Appln. No. 2017228612 dated Jun. 8, 2018, 3 pages. [cited by applicant]
Examination Report for IN Appln. No. 201627023163 dated Aug. 31, 2018, 6 pages. [cited by applicant]
Extended European Search Report for EP Appln. No. 18156034.3 dated Jun. 6, 2018, 6 pages. [cited by applicant]
Extended European search report for European Application No. 19177110.4 dated Dec. 13, 2019. (1O paoes). [cited by applicant]
Extended European Search Report mailed on Apr. 26, 2012, for EP 09 83 2229, filed on Jun. 21, 2011, 6 pages. (28.48). [cited by applicant]
Extended European Search Report mailed on Jul. 27, 2012, for EP 09 83 2228.2, filed on Jun. 21, 2011, 12 pages. (27.49). [cited by applicant]
Extended European Search Report mailed on Mar. 12, 2014, for EP 13005979.3, filed on Dec. 20, 2013, 5 pages. (27.64). [cited by applicant]
Final Office Action mailed on Jan. 27, 2012, for U.S. Appl. No. 12/632,151, filed Dec. 7, 2009, 15 pages. (28.00). [cited by applicant]
Final Office Action mailed on May 2, 2013 for U.S. Appl. No. 13/343,624, filed Jan. 4, 2012, 9 pages. (38.01). [cited by applicant]
Final Office Action mailed on May 25, 2012, for U.S. Appl. No. 12/632,140, filed Dec. 7, 2009, 9 pages. (27.00). [cited by applicant]
Final Office Action mailed on Oct. 30, 2012, for U.S. Appl. No. 12/632,140, filed Dec. 7, 2009, 9 pages. (27.00). [cited by applicant]
Final Office Action mailed on Sep. 15, 2011, for U.S. Appl. No. 12/632,140, filed Dec. 7, 2009, 15 pages. (27.00). [cited by applicant]
Final Office Action mailed on Sep. 5, 2012, for U.S. Appl. No. 12/632,151, filed Dec. 7, 2009, 11 pages. (28.00). [cited by applicant]
International Preliminary Examination Report mailed on Aug. 5, 2004, for PCT Application No. PCT/US2003/12222, filed Apr. 21, 2003, 11 pages. [cited by applicant]
International Preliminary Examination Report mailed on Oct. 27, 2004, for PCT Application No. PCT/US2003/28329, filed on Sep. 9, 2003, 5 oaaes. [cited by applicant]
International Preliminary Report on Patentab ty mailed on Aug. 17, 2010, for PCT Application No. PCT/US2009/000919, filed on Feb. 12, 2009, 8 pages. (38.40). [cited by applicant]
International Preliminary Report on Patentab ty mailed on Jan. 5, 2011, for PCT Application No. PCT/US2009/006445, filed on Dec. 7, 2009, 6 pages. (27.40). [cited by applicant]
International Preliminary Report on Patentab ty mailed on Oct. 29, 2010, for PCT Application No. PCT/US/2009/006446, filed on Dec. 7, 2009, 6 pages. (28.40). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2014/049032 dated Sep. 19, 2014. (8 pages). [cited by applicant]
International Search Report and Written Opinion mailed Mar. 3, 2015, for PCT Application No. PCT/US2014/068423, Filed Dec. 3, 2014. [cited by applicant]
International Search Report and Written Opinion mailed Oct. 13, 2014, for PCT Application No. PCT/US2014/048741, Filed Jul. 29, 2014. [cited by applicant]
International Search Report and Written Opinion mailed on Dec. 30, 2004, for PCT Aoolication No. PCT/US2004/018227, filed on Jun. 4, 2004, 10 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Dec. 8, 2004, for PCT Application No. PCT/US2004/021150, filed on Jun. 30, 2004, 10 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Feb. 1, 2005 for PCT Application No. PCT/US2004/025884, filed on Aug. 11, 2004, 8 oaaes. [cited by applicant]
International Search Report and Written Opinion mailed on Jul. 7, 2004, for PCT Application No. PCT/US2004/003922, filed on Feb. 10, 2004, 12 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Jul. 7, 2004, for PCT Application No. PCT/US2004/003923, filed on Feb. 10, 2004, 12 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Jun. 23, 2005, for PCT Application No. PCT/US2004/037433, filed on Nov. 10, 2004, 15 paqes. [cited by applicant]
International Search Report and Written Opinion mailed on Oct. 8, 2014, for PCT Application No. PCT/US2014/048733, filed on Jul. 29, 2014. [cited by applicant]
International Search Report mailed Apr. 26, 2011, for Application No. PCT/US2011/028194, filed on Mar. 11, 2011, 5 oaaes. (39.40). [cited by applicant]
International Search Report mailed on Feb. 12, 2010, for PCT Application No. PCT/US/2009/006446, filed on Dec. 7, 2009, 3 pages. (28.40). [cited by applicant]
International Search Report mailed on Feb. 12, 2010, for PCT Application No. PCT/US2009/006445, filed on Dec. 7, 2009, 3 pages. (27.40). [cited by applicant]
International Search Report mailed on Feb. 9, 2004, for PCT Application No. PCT/US2003/28329, filed on Sep. 9, 2003. [cited by applicant]
International Search Report mailed on May 12, 2009, for PCT Application No. PCT/US2009/000919, filed on Feb. 12, 2009, 5 paqes. (38.40). [cited by applicant]
International Search Report mailed on Oct. 22, 2003, for PCT Application No. PCT/US2003/12222, filed on Apr. 21, 2003. [cited by applicant]
Invitation to Pay Additional Fees with Partial International Search Report mailed May 3, 2005, for PCT Application No. PCT/US2004/037433, filed on Nov. 10, 2004, 9 pages. [cited by applicant]
Japanese Decision of Patent mailed Feb. 4, 2014, for Japanese Patent Application No. 2010-546786, filed on Aug. 1, 2010, 4 oaaes. (with Enalish translation). (38.45). [cited by applicant]
Japanese Notice of Reasons for Rejection mailed on Feb. 4, 2014 for Japanese Patent Application No. 2011-539524, filed on Jun. 6, 2011, 10 pages. (with English translation). (27.53). [cited by applicant]
Japanese Notice of Reasons for Rejection mailed on Feb. 6, 2014, for Japanese Patent Application No. 2011-539525, filed on Jun. 6, 2011, 11 pages. (with English translation). (28.52). [cited by applicant]
Non-Final Office Action mailed on Apr. 13, 2011 for U.S. Appl. No. 12/370,103, filed Feb. 12, 2009, 11 pages. (38.00). [cited by applicant]
Non-Final Office Action mailed on Apr. 3, 2006, for U.S. Appl. No. 10/776,002, filed Feb. 10, 2004, 13 oaaes. (33.30). [cited by applicant]
Non-Final Office Action mailed on Dec. 31, 2013, for U.S. Appl. No. 13/901,523, filed May 23, 2013, 22 pages. (27.02). [cited by applicant]
Non-Final Office Action mailed on Feb. 17, 2012 for U.S. Appl. No. 12/632,140, filed Dec. 7, 2009, 11 pages. (27.00). [cited by applicant]
Non-Final Office Action mailed on Jan. 25, 2013, for U.S. Appl. No. 13/343,624, filed Jan. 4, 2012, 18 pages. (38.01). [cited by applicant]
Non-Final Office Action mailed on Jan. 8, 2007, for U.S. Appl. No. 10/915,696, filed Aug. 11, 2004, 8 pages. (34.00). [cited by applicant]
Non-Final Office Action mailed on Jun. 29, 2011, for U.S. Appl. No. 12/632,151, filed Dec. 7, 2009, 17 pages. (28.00). [cited by applicant]
Non-Final Office Action mailed on May 10, 2011 for U.S. Appl. No. 12/632,140, filed Dec. 7, 2009, 18 pages. (27.00). [cited by applicant]
Non-Final Office Action mailed on May 17, 2012, for U.S. Appl. No. 12/632,151, filed Dec. 7, 2009, 15 paoes. (28.00). [cited by applicant]
Non-Final Office Action mailed on May 24, 2006, for U.S. Appl. No. 10/776,631, filed Feb. 10, 2004, 10 pages. (33.00). [cited by applicant]
Non-Final Office Action mailed on Nov. 4, 2013, for U.S. Appl. No. 13/862,147, filed Apr. 12, 2013, 18 oaaes. (28.01). [cited by applicant]
Non-Final Office Action mailed on Oct. 11, 2012, for U.S. Appl. No. 13/441,441, filed Apr. 6, 2012, 8 pages. (27.20). [cited by applicant]
Non-Final Office Action mailed on Oct. 11, 2013, for U.S. Appl. No. 13/868,967, filed Apr. 23, 2013, 17 pages. (27.01). [cited by applicant]
Non-Final Office Action mailed on Oct. 16, 2013, for U.S. Appl. No. 13/868,971, filed Apr. 23, 2013, 16 pages. (27.10). [cited by applicant]
Non-Final Office Action mailed on Sep. 26, 2006, for U.S. Appl. No. 10/658,121, filed Sep. 9, 2003, 7 paqes. (32.00). [cited by applicant]
Notice of Allowance mailed Apr. 20, 2007, for U.S. Appl. No. 10/915,696, filed Aug. 11, 2004, 7 pages. (34.00). [cited by applicant]
Notice of Allowance mailed Aug. 11, 2006, for U.S. Appl. No. 10/776,002, filed Feb. 10, 2004, 10 paqes. (33.30). [cited by applicant]
Notice of Allowance mailed Aug. 8, 2007, for U.S. Appl. No. 10/658,121, filed Sep. 9, 2003, 4 pages. (32.00). [cited by applicant]
Notice of Allowance mailed Mar. 6, 2007, for U.S. Appl. No. 10/658,121, filed Sep. 9, 2003, 6 oaaes. (32.00). [cited by applicant]
Notice of Allowance mailed on Aug. 12, 2013, for U.S. Appl. No. 13/343,624, filed Jan. 4, 2012 , 9 pages. (38.01). [cited by applicant]
Notice of Allowance mailed on Dec. 26, 2013, for U.S. Appl. No. 13/343,624, filed Jan. 4, 2012 , 10 paqes. (38.01). [cited by applicant]
Notice of Allowance mailed on Feb. 12, 2014, for U.S. Appl. No. 13/862,147, filed Apr. 12, 2013, 9 pages. (28.01). [cited by applicant]
Notice of Allowance mailed on Feb. 5, 2014, for U.S. Appl. No. 13/868,967, filed Apr. 23, 2013, 8 oaaes. (27.01). [cited by applicant]
Notice of Allowance mailed on Jan. 14, 2013, for U.S. Appl. No. 12/632,151, filed Dec. 7, 2009, 8 pages. (28.00). [cited by applicant]
Notice of Allowance mailed on Jan. 25, 2013, for U.S. Appl. No. 12/632,140, filed Dec. 7, 2009, 8 pages. (27.00). [cited by applicant]
Notice of Allowance mailed on Jan. 28, 2013, for U.S. Appl. No. 13/441,441, filed Apr. 6, 2012, 8 pages. (27.20). [cited by applicant]
Notice of Allowance mailed on Jan. 30, 2014, for U.S. Appl. No. 13/868,971, filed Apr. 23, 2013, 8 paqes. (27.10). [cited by applicant]
Notice of Allowance mailed Sep. 7, 2006, for U.S. Appl. No. 10/776,631, filed Feb. 10, 2004, 7 pages. (33.00). [cited by applicant]
Office Action Dated Dec. 15, 2014 for Japan Patent Application No. 2014-095907. [cited by applicant]
Office Action Dated Jan. 15, 2015 for Chilean Patent Application No. 1360-11. [cited by applicant]
Office Action Dated Jan. 30, 2015 for Vietnamese Patent Application No. 1-2011-01623. [cited by applicant]
Office Action Dated Feb. 18, 2015 for Eurasian Patent Application No. 201400197. [cited by applicant]
Office Action Dated Mar. 30, 2015 for European Patent Application No. 13 005 979.3. [cited by applicant]
Office Action dated Jun. 8, 2017 for JP Appl. No. 2016-560876, 3 pages. [cited by applicant]
Office Action for BO Appln. No. SP-0316-2014 dated Aug. 2, 2018, 2 pages. [cited by applicant]
Office Action for BO Appln. No. SP-0316-2014 dated Feb. 8, 2018, 5 pages. [cited by applicant]
Office Action for CL Appln. No. 1537-2016 dated Sep. 20, 2018, 7 pages. [cited by applicant]
Office Action for CU Appln. No. 2016-0097 dated May 17, 2018, 2 pages. [cited by applicant]
Office Action for DO Appln. No. P2016-0140 dated Feb. 13, 2018, 2 pages. [cited by applicant]
Office Action for DO Appln. No. P2016-0140 dated Oct. 12, 2018, 2 pages. [cited by applicant]
Office Action for JP Appln. No. 2017-172941 dated Nov. 22, 2018, 2 pages. [cited by applicant]
Office Action for SV Appln. No. 2016005229 dated May 2, 2018, 6 pages. [cited by applicant]
Office Action for TT Appln. No. TT/A/2016/00058 dated Jun. 8, 2018, 1 page. [cited by applicant]
Office Action for TW Appln. No. 103144664 dated Jul. 6, 2018, 4 pages. [cited by applicant]
Office Action for UA Appln. No. A201606436 dated Jun. 17, 2018, 4 pages. [cited by applicant]
Office Action for UA Appln. No. A201606436 dated Mar. 1, 2018, 5 pages. [cited by applicant]
Partial European Search Report for European Application No. 19177110.4 dated Aug. 29, 2019 (1O pages). [cited by applicant]
Resolution Dated Dec. 18, 2014 for Colombian Patent Application No. 14-049.611. [cited by applicant]
Restriction Requirement mailed Dec. 8, 2010, for U.S. Appl. No. 12/632,140, filed Dec. 7, 2009, 1O oaaes. (27.00). [cited by applicant]
Restriction Requirement mailed Jan. 27, 2006, for U.S. Appl. No. 10/776,631, filed Feb. 10, 2004, 6 pages. (33.00). [cited by applicant]
Restriction Requirement mailed Jan. 30, 2006, for U.S. Appl. No. 10/658,121, filed Sep. 9, 2003, 5 pages. (32.00). [cited by applicant]
Restriction Requirement mailed Jan. 4, 2006, for U.S. Appl. No. 10/776,002, filed Feb. 10, 2004, 7 pages. (33.30). [cited by applicant]
Restriction Requirement mailed May 18, 2006, for U.S. Appl. No. 10/658,121, filed Sep. 9, 2003, 5 pages. (32.00). [cited by applicant]
Restriction Requirement mailed Oct. 13, 2006, for U.S. Appl. No. 10/915,696, filed Aug. 11, 2004, 5 pages. (34.00). [cited by applicant]
Restriction Requirement mailed Oct. 20, 2004, for U.S. Appl. No. 10/419,682, filed Apr. 21, 2003, 9 paoes. [cited by applicant]
Restriction Requirement mailed on Apr. 14, 2014, for U.S. Appl. No. 13/862,194, filed Apr. 12, 2013, 5 pages. (28.10). [cited by applicant]
Restriction Requirement mailed on Dec. 8, 2010, for U.S. Appl. No. 12/632,151, filed Dec. 7, 2009, 10 oaaes. (28.00). [cited by applicant]
Restriction Requirement mailed on Feb. 17, 2011, for U.S. Appl. No. 12/370,103, filed Feb. 12, 2009, 10 pages. (38.00). [cited by applicant]
Restriction Requirement mailed on Jan. 27, 2014, for U.S. Appl. No. 13/609,068, filed Nov. 26, 2012, 8 pages. (39.00). [cited by applicant]
Restriction Requirement mailed on Jul. 26, 2012, for U.S. Appl. No. 13/441,441, filed Apr. 6, 2012, 9 pages. (27.20). [cited by applicant]
Restriction Requirement mailed on Jul. 3, 2013, for U.S. Appl. No. 13/868,971, filed Apr. 23, 2013, 5 paqes. (27.10). [cited by applicant]
Restriction Requirement mailed on Jun. 14, 2013, for U.S. Appl. No. 13/862,147, filed Apr. 12, 2013, 1O pages. (28.01). [cited by applicant]
Restriction Requirement mailed on Jun. 24, 2013, for U.S. Appl. No. 13/868,967, filed Apr. 23, 2013, 1O paoes. (27.01). [cited by applicant]
Restriction Requirement mailed on Nov. 27, 2012, for U.S. Appl. No. 13/343,624, filed Jan. 4, 2012, 10 pages. (38.01). [cited by applicant]
Restriction Requirement mailed on Oct. 15, 2013, for U.S. Appl. No. 13/901,523, filed May 23, 2013, 5 paoes. (27.02). [cited by applicant]
Restriction Requirement mailed on Sep. 8, 2014, for U.S. Appl. No. 14/274,618, filed May 9, 2014, 6 pages. (27.03). [cited by applicant]
Second Written Opinion mailed on Apr. 13, 2004, for PCT Application No. PCT/US2003/12222, filed Apr. 21, 2003, 7 oaaes. [cited by applicant]
Written Opinion mailed Apr. 26, 2011, for Application No. PCT/US2011/028194, filed on Mar. 11, 2011, 6 pages. (39.40). [cited by applicant]
Written Opinion mailed Dec. 5, 2003, for PCT Application No. PCT/US2003/12222, filed Apr. 21, 2003, 6 pages. [cited by applicant]
Written Opinion mailed Jul. 6, 2004, for PCT Application No. PCT/US2003/28329, filed on Sep. 9, 2003, 5 pages. (32.40). [cited by applicant]
Written Opinion mailed on Feb. 12, 2010, for PCT Application No. PCT/US/2009/006446, filed on Dec. 7, 2009, 4 paoes. (28.40). [cited by applicant]
Written Opinion mailed on Feb. 12, 2010, for PCT Application No. PCT/US2009/006445, filed on Dec. 7, 2009, 4 pages. (27.40). [cited by applicant]
Written Opinion mailed on May 12, 2009, for PCT Application No. PCT/US2009/000919, filed on Feb. 12, 2009, 7 pages.(38.40). [cited by applicant]
Caira, Jan. 1998, Crystalline polymorphism of organic compounds, Topics in Current Chemistry, 198:163-208. [cited by applicant]
Sarma et al., 2011, Solid formation of pharmaceuticals: Polymorphs, salt and cocrystals. Korean J.Chem.Eng., 28(2):315-322. [cited by applicant]
Variankaval et al., 2008, From form to function: Crystallization of active pharmaceutical ingredients, AlChE, 54(7):1682-1688. [cited by applicant]